Why the study?
In acute massive PE secondary to cardiac arrest treated with VA-ECMO, the safety and necessity of combined thrombolytic therapy remain controversial.
Does combined thrombolytic therapy improve outcomes or increase bleeding risk in patients with acute massive pulmonary embolism and cardiac arrest treated with VA-ECMO?
Does combined thrombolytic therapy improve outcomes or increase bleeding risk in patients with acute massive pulmonary embolism and cardiac arrest treated with VA-ECMO?
In patients with acute massive pulmonary embolism and cardiac arrest treated with VA-ECMO, combined thrombolysis may lead to fatal bleeding complications, highlighting the need for individualized reperfusion strategies.
Supports feasibility of VA-ECMO without thrombolysis in PE-CA; leaves open role of adjunctive lysis pending controlled data.
Acute massive pulmonary embolism (PE) secondary to cardiac arrest (CA) is associated with extremely high mortality. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) serves as a critical life support modality; however, the safety and necessity of combined thrombolytic therapy remain controversial. This study reports the clinical outcomes of two CA patients with acute PE treated with VA-ECMO: Case 1 underwent ECMO support without thrombolysis, receiving only heparin anticoagulation. Dynamic imaging evaluation demonstrated gradual thrombus resolution, leading to successful weaning from ECMO and subsequent recovery. Case 2 received immediate thrombolysis with alteplase 50 mg after ECMO cannulation but succumbed to severe bleeding complications-including cannulation site hemorrhage, disseminated intravascular coagulation (DIC), and hemorrhagic shock-within 24 h. For ECMO-treated PE patients with CA, clinical decisions should be based on etiological assessment, bleeding risk, and multimodal evaluations (e.g., imaging, coagulation function), prioritizing individualized reperfusion strategies (such as catheter-directed thrombectomy or surgical embolectomy) to improve prognosis. Although both cases described herein received VA-ECMO as salvage therapy, their divergent thrombolytic strategies resulted in contrasting clinical outcomes, prompting critical clinical reflections on risk-benefit balancing in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: